摘要
通过考察酮康唑固体脂质纳米粒体外透皮情况,由结果预测固体脂质纳米粒的发展前景。方法制备酮康唑固体脂质纳米粒,并测定2 h、4 h、6 h、8 h、12 h、24 h时间点的药物累积透过皮肤与潴留于皮肤的量,通过数据分析评价药物在固体脂质纳米粒里的体外释放及透皮情况。结果药物在固体脂质纳米粒里的皮肤累积透过量低于含药1%的乳膏,但固体脂质纳米粒的皮肤潴留量明显高于含药1%的乳膏。结论固体脂质纳米粒可增加药物在皮肤的局部浓度从而增强药效,同时可减少药物透过真皮进入体循环从而减少副作用,具有良好的发展前景。
Forcast solid lipid nanoparticle＇s use in the future through study the ketoconazole loaded in solid lipid nanoparticle about transdermal and retention in derma. Method Prepare solid lipid nanoparticle and determine 2 h, 4 h, 6 h, 8 h, 12 h, 24 h time-points with TK-12B and LC-20A chiefly, get the quantity of medicine transdemaal and retention in derma. In this way we could know something about in vitro release and transdermal of SLN. Results The quantity of medicine transdermal is less than the cream of 1%, but the quantity of retention in derma is more than cream of 1%. Conclusions Solid lipid nanopartiele can increase medicine retention in derma, therefore, the efficacy can be increase. What is more, solid lipid nanoparticle can reduce medicine transdermal, so that, solid lipid nanoparticle will reduce the side effect of the medicine. All of above, solid lipid nanoparticle will be used widely in the future.
出处
《广东化工》
CAS
2013年第23期48-49,共2页
Guangdong Chemical Industry
关键词
酮康唑
固体脂质纳米粒
体外释放
透皮
潴留
新剂型
：ketoconazole： solid lipid nanoparticle
in vitro release
transdermal
retention
new formulation
